Pavmed INC DEF 14A proxy statements

PAVmed Inc. has issued its 2026 proxy statement detailing proposals for director elections, an ESPP amendment, and auditor ratification.

PAVmed Inc. calls a special meeting to approve significant equity issuances, a corporate governance amendment, and an increase in its equity incentive plan, following a $30 million private placement and debt refinancing.

PAVmed Inc. will hold a special meeting on December 5, 2025, to seek stockholder approval for a reverse stock split and a reduction in authorized common stock to regain Nasdaq compliance and attract institutional investors.

PAVmed Inc. supplements its proxy statement to include the full text of the amended 2014 Long-Term Incentive Equity Plan for the upcoming annual meeting.

Pavmed Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

PAVmed Inc. is soliciting proxies for its annual meeting on June 18, 2025, to vote on key proposals including director elections, stock issuance approval, an equity plan amendment, executive compensation, and auditor ratification.

PAVmed Inc. has updated its proxy statement to reflect that all proposals for the upcoming special meeting of stockholders on January 15, 2025, are now classified as non-routine matters.

PAVmed Inc. is holding a special meeting to seek stockholder approval for a debt exchange, a securities purchase agreement, and an increase in authorized common stock to address Nasdaq listing requirements and financial obligations.

Pavmed Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

PAVmed Inc. will hold its annual stockholder meeting on June 20, 2024, to elect two Class B directors and ratify the appointment of Marcum LLP as its independent accounting firm.